Matthew Keeler's questions to LEAP THERAPEUTICS (LPTX) leadership • Q1 2015
Question
Matthew Keeler of Credit Suisse asked for clarification on the upcoming VLU trial futility analysis and inquired about physician feedback on CureXcell's mechanism of action data presented at the Symposium for Advanced Wound Care (SAWC).
Answer
President and CEO Nissim Mashiach explained the futility analysis has three potential outcomes based on probability of success, with the company anticipating a recommendation to continue the trial. Chief Medical Officer Mike Molyneaux added that feedback at SAWC was 'extremely positive,' with physicians excited by the robust and differentiated data presented.